ARACYTINE

Aracytine Adverse Events Reported to the FDA Over Time

How are Aracytine adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Aracytine, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Aracytine is flagged as the suspect drug causing the adverse event.

Most Common Aracytine Adverse Events Reported to the FDA

What are the most common Aracytine adverse events reported to the FDA?

Pyrexia	32 (2.51%)
Thrombocytopenia	23 (1.8%)
Renal Failure Acute	22 (1.72%)
Cytolytic Hepatitis	18 (1.41%)
Febrile Bone Marrow Aplasia	17 (1.33%)
Pancytopenia	17 (1.33%)
Bone Marrow Failure	15 (1.17%)
Renal Failure	15 (1.17%)
Pneumonia	14 (1.1%)
Pleural Effusion	13 (1.02%)
Cerebellar Syndrome	12 (.94%)
	Show More
Confusional State	12 (.94%)
Pancreatitis Acute	12 (.94%)
Respiratory Distress	12 (.94%)
Blood Bilirubin Increased	11 (.86%)
Diarrhoea	11 (.86%)
Sepsis	11 (.86%)
Toxic Skin Eruption	11 (.86%)
Condition Aggravated	10 (.78%)
Hypotension	10 (.78%)
Leukopenia	10 (.78%)
Coma	9 (.7%)
Gamma-glutamyltransferase Increased	9 (.7%)
Hyperthermia	9 (.7%)
Mydriasis	9 (.7%)
Somnolence	9 (.7%)
Agranulocytosis	8 (.63%)
Blood Alkaline Phosphatase Increase...	8 (.63%)
Cardio-respiratory Arrest	8 (.63%)
Cholestasis	8 (.63%)
Convulsion	8 (.63%)
Lung Disorder	8 (.63%)
Neutropenia	8 (.63%)
Vasculitis Cerebral	8 (.63%)
Abdominal Pain	7 (.55%)
Acute Myeloid Leukaemia	7 (.55%)
Alanine Aminotransferase Increased	7 (.55%)
Aspartate Aminotransferase Increase...	7 (.55%)
Bronchopulmonary Aspergillosis	7 (.55%)
Cardiac Failure	7 (.55%)
Hepatic Failure	7 (.55%)
Hypertension	7 (.55%)
Septic Shock	7 (.55%)
Tachycardia	7 (.55%)
Tachypnoea	7 (.55%)
Vomiting	7 (.55%)
Anaemia	6 (.47%)
Aplasia	6 (.47%)
Balance Disorder	6 (.47%)
Bilirubin Conjugated Increased	6 (.47%)
Cardiac Arrest	6 (.47%)
Death	6 (.47%)
Dermatitis Bullous	6 (.47%)
Febrile Neutropenia	6 (.47%)
Hyperbilirubinaemia	6 (.47%)
Hypernatraemia	6 (.47%)
Interstitial Lung Disease	6 (.47%)
Mucosal Inflammation	6 (.47%)
Staphylococcal Infection	6 (.47%)
Stevens-johnson Syndrome	6 (.47%)
Tremor	6 (.47%)
Venoocclusive Liver Disease	6 (.47%)
Acute Pulmonary Oedema	5 (.39%)
Anuria	5 (.39%)
Ataxia	5 (.39%)
Blood Creatinine Increased	5 (.39%)
Dysarthria	5 (.39%)
Escherichia Infection	5 (.39%)
Eye Movement Disorder	5 (.39%)
Hepatitis Cholestatic	5 (.39%)
Nausea	5 (.39%)
Oedema Peripheral	5 (.39%)
Oxygen Saturation Decreased	5 (.39%)
Sinus Bradycardia	5 (.39%)
Ventricular Fibrillation	5 (.39%)
Acute Leukaemia	4 (.31%)
Acute Respiratory Distress Syndrome	4 (.31%)
Arrhythmia	4 (.31%)
Ascites	4 (.31%)
Bacteraemia	4 (.31%)
Blood Lactate Dehydrogenase Increas...	4 (.31%)
Body Temperature Increased	4 (.31%)
Cerebral Haemorrhage	4 (.31%)
Cheilitis	4 (.31%)
Chills	4 (.31%)
Decerebration	4 (.31%)
Drug Toxicity	4 (.31%)
Dyspnoea	4 (.31%)
Encephalopathy	4 (.31%)
Escherichia Sepsis	4 (.31%)
Gait Disturbance	4 (.31%)
Haemoglobin Decreased	4 (.31%)
Haemoptysis	4 (.31%)
Hepatic Steatosis	4 (.31%)
Hypoxia	4 (.31%)
Jaundice	4 (.31%)
Lipase Increased	4 (.31%)
Liver Disorder	4 (.31%)
Lymphadenitis	4 (.31%)
Myocardial Infarction	4 (.31%)
Necrotising Ulcerative Gingivostoma...	4 (.31%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Aracytine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Aracytine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Aracytine

What are the most common Aracytine adverse events reported to the FDA?

Hepatic And Hepatobiliary	72 (5.64%)
Neurological	70 (5.48%)
Respiratory	61 (4.78%)
Anemias Nonhemolytic And Marrow Dep...	56 (4.39%)
Infections - Pathogen Unspecified	54 (4.23%)
Hepatobiliary	46 (3.6%)
Renal Disorders	43 (3.37%)
Body Temperature Conditions	41 (3.21%)
Cardiac Arrhythmias	41 (3.21%)
Epidermal And Dermal Conditions	41 (3.21%)
White Blood Cell	35 (2.74%)
	Show More
Bacterial Infectious	31 (2.43%)
Gastrointestinal Signs	31 (2.43%)
Hematology Investigations	26 (2.04%)
Central Nervous System Vascular	24 (1.88%)
Platelet	24 (1.88%)
Lower Respiratory Tract Disorders	22 (1.72%)
Fungal Infectious	19 (1.49%)
Ocular Neuromuscular	18 (1.41%)
Movement Disorders	17 (1.33%)
Leukemias	16 (1.25%)
Gastrointestinal Motility And Defec...	15 (1.17%)
Decreased And Nonspecific Blood Pre...	13 (1.02%)
Enzyme	13 (1.02%)
Pleural	13 (1.02%)
Deliria	12 (.94%)
Electrolyte And Fluid Balance Condi...	12 (.94%)
Exocrine Pancreas Conditions	12 (.94%)
Seizures	12 (.94%)
Heart Failures	10 (.78%)
Injuries	10 (.78%)
Vision	10 (.78%)
Fatal Outcomes	9 (.7%)
Gastrointestinal	9 (.7%)
Peripheral Neuropathies	9 (.7%)
Physical Examination Topics	9 (.7%)
Urinary Tract Signs	9 (.7%)
Oral Soft Tissue Conditions	8 (.63%)
Spleen, Lymphatic And Reticulendoth...	8 (.63%)
Chemical Injury And Poisoning	7 (.55%)
Encephalopathies	7 (.55%)
Medication Errors	7 (.55%)
Peritoneal And Retroperitoneal Cond...	7 (.55%)
Renal And Urinary Tract Investigati...	7 (.55%)
Vascular Hypertensive	7 (.55%)
Viral Infectious	7 (.55%)
Congenital And Hereditary	6 (.47%)
Coronary Artery	6 (.47%)
Cranial Nerve Disorders	6 (.47%)
Neonatal And Perinatal Conditions	6 (.47%)
Blood And Lymphatic System Disorder...	5 (.39%)
Central Nervous System Infections A...	5 (.39%)
Gastrointestinal Conditions	5 (.39%)
Increased Intracranial Pressure And...	5 (.39%)
Metabolic, Nutritional And Blood Ga...	5 (.39%)
Respiratory And Pulmonary Investiga...	5 (.39%)
Spinal Cord And Nerve Root	5 (.39%)
Anxiety Disorders	4 (.31%)
Appetite And General Nutritional	4 (.31%)
Cardiac And Vascular Investigations	4 (.31%)
Joint	4 (.31%)
Microbiology And Serology	4 (.31%)
Miscellaneous And Site Unspecified ...	4 (.31%)
Myocardial	4 (.31%)
Pericardial	4 (.31%)
Upper Respiratory Tract Disorders	4 (.31%)
Water, Electrolyte And Mineral	4 (.31%)
Angiedema And Urticaria	3 (.23%)
Embolism And Thrombosis	3 (.23%)
Eye	3 (.23%)
Headaches	3 (.23%)
Hematological And Lymphoid Tissue T...	3 (.23%)
Hematopoietic Neoplasms	3 (.23%)
Neoplasm Related Morbidities	3 (.23%)
Neuromuscular	3 (.23%)
Protein And Chemistry Analyses	3 (.23%)
Therapeutic Procedures And Supporti...	3 (.23%)
Bladder And Bladder Neck Disorders	2 (.16%)
Coagulopathies And Bleeding Diathes...	2 (.16%)
Depressed Mood Disorders	2 (.16%)
Disturbances In Thinking	2 (.16%)
Fetal Complications	2 (.16%)
Gallbladder	2 (.16%)
Gastrointestinal Hemorrhages	2 (.16%)
Gastrointestinal Inflammatory Condi...	2 (.16%)
Gastrointestinal Vascular Condition...	2 (.16%)
Immune	2 (.16%)
Immunodeficiency Syndromes	2 (.16%)
Lipid Metabolism	2 (.16%)
Lymphomas	2 (.16%)
Metabolism	2 (.16%)
Muscle	2 (.16%)
Neurological, Special Senses And Ps...	2 (.16%)
Pregnancy, Labour, Delivery And Pos...	2 (.16%)
Pulmonary Vascular	2 (.16%)
Respiratory Tract Therapeutic Proce...	2 (.16%)
Skin Vascular Abnormalities	2 (.16%)
Structural Brain	2 (.16%)
Therapeutic And Nontherapeutic Effe...	2 (.16%)
Vascular	2 (.16%)
Breast Neoplasms Malignant And Unsp...	1 (.08%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Aracytine, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Aracytine is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.